Patent ID: 8017321
Filing Date: 2011-09-13
Classification: A61P,C12Q

Abstract:
1. A method to select a lung cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor selected from the group consisting of gefitinib and erlotinib comprising: a) detecting the level of E-cadherin polynucleotides in a sample of tumor cells from said patient; b) comparing said level to a level of E-cadherin polynucleotides in a sample of tumor cells from a subject having lung cancer that is resistant to gefitinib; and, c) selecting the patient as being predicted to benefit from therapeutic administration of an EGFR inhibitor, selected from the group consisting of gefitinib and erlotinib, if the level of E-cadherin polynucleotides in the sample of tumor cells from said patient is higher than the level of E-cadherin polynucleotides in the sample of tumor cells from the subject that is resistant to gefitinib.